AI Breakthroughs Drive New Momentum in Oncology Research
Source: Streetwise Reports  (12/3/25)
Rakovina Therapeutics Inc. (RKV:TSX.V) reported financial and operational results for Q3, detailing continued progress across its AI-enabled DNA Damage Response programs. The company highlighted new scientific data, expanded collaborations, and increased visibility at major oncology conferences. More >

Analyst: Scientific Instrument Co.'s Q3/25 Results 'Soft'
Source: Dr. Douglas Loe  (12/2/25)
Nanalysis Scientific Corp. (NSCI:TSX.V; NSCIF:OTC; 1N1:FSE) has its price target lowered as a result, but is expected to improve its financials in the near term, noted a Leede Financial Inc. report. More >

Biotech Co. Advances Precision Psychiatry Breakthrough Pipeline While Analysts' Sentiment Remains Positive
Source: Streetwise Reports  (12/1/25)
Alto Neuroscience Inc. (ANRO:NYSE) continues moving its clinical programs forward, receives regulatory clarity and raises US$50 million, during the past four months. Read on for analysts' thoughts on this biopharma. More >

Biotech Co.'s Q3/25 Progress on Lead Programs Steady
Source: Patrick Trucchio  (12/1/25)
Alto Neuroscience Inc.'s (ANRO:NYSE) clinical execution and regulatory momentum advance the firm's biomarker-guided precision psychiatry pipeline, noted an H.C. Wainwright & Co. report. More >

AI Identifies Preclinical Cancer Compounds With Potential to Reach the Brain
Source: Streetwise Reports  (11/26/25)
Rakovina Therapeutics Inc. (RKV:TSX.V) presented new data at the 2025 Society for Neuro-Oncology Annual Meeting on its PARP1-selective inhibitors, with central nervous system penetration. The findings demonstrated how Rakovina's AI-powered discovery platform identified promising drug candidates designed to target brain-involved cancers. More >

Clean Tech Co.: Wound Care Subsidiary Set to Take Off; 3Q Results
Source: Streetwise Reports  (11/19/25)
Clean technology innovation company BioLargo Inc. releases its financial and operational results for the three- and nine-month periods ending September 30. It also has announced an agreement to distribute its cutting-edge wound irrigation solution nationally. More >

US$12 Billion RNA Deal Triggers Sector Shakeup
Source: Streetwise Reports  (11/14/25)
Avidity Biosciences Inc. (RNA:NASDAQ) reported Q3 results alongside news of its US$12 billion acquisition by Novartis. The deal comes as three RNA drugs approach major regulatory filings through 2026. More >

Preclinical Compounds Perform Better Than Existing Drugs
Source: Dr. Douglas Loe  (11/13/25)
Rakovina Therapeutics Inc.'s (RKV:TSX.V) AI-designed Compounds A, B and C demonstrated the same ATR blocking activity as three of Big Pharma's existing, clinical-stage drugs but at much lower concentrations, noted a Leede Financial Inc. report. More >

Lead Drug Faces Uncertain FDA Path After Phase 3 Miss
Source: Streetwise Reports  (11/13/25)
aTyr Pharma Inc. (ATYR:NASDAQ) is seeking regulatory clarity following mixed Phase 3 results for its lead candidate efzofitimod in pulmonary sarcoidosis. The company expects feedback from the FDA in the first quarter of 2026 to help determine a potential path forward. More >

Breakthrough Pill Cuts Bad Cholesterol by Nearly 60% in Major Trials
Source: Streetwise Reports  (11/12/25)
Merck & Co. Inc. (MRK:NYSE) announced that its investigational oral PCSK9 inhibitor, enlicitide, achieved significant LDL-C reductions in two pivotal Phase 3 studies presented at the American Heart Association Scientific Sessions. The once-daily pill demonstrated efficacy comparable to injectable therapies, marking a major step forward in cholesterol management. More >

Clean Tech Finds Massive Energy Savings in PFAS Treatment
Source: Streetwise Reports  (11/5/25)
BioLargo Inc. (BLGO:OTCQX) announces a significant upgrade to its patented Aqueous Electrostatic Concentrator (AEC) system, reducing energy consumption by over 90% in large-scale "forever chemical" treatment for drinking water. More >

Biotech to Fast Track Phase 3 Depression Trial
Source: Dr. Myles Minter  (10/30/25)
Alto Neuroscience Inc. (ANRO:NYSE) intends to carry out this newly added study, supported by a recent financing, and the previously planned Phase 2b trial simultaneously, noted a William Blair report. More >

2 Key Catalysts Ahead for Developer of Psych Drugs
Source: Patrick Trucchio  (10/28/25)
Alto Neuroscience Inc. (ANRO:NYSE) expects to release topline trial data in 2025 and commence a separate study in 2026, noted an H.C. Wainwright & Co. report. More >

Co. Speeds Up Development of New Drug for Depression
Source: Andrew Tsai  (10/28/25)
Alto Neuroscience Inc. (ANRO:NYSE) plans Phases 2b and 3 trials of its asset, ALTO-207, in treatment-resistant depression, noted a Jefferies report. More >

Price Target on Psychiatric Drug Biotech Boosted 200%
Source: Dr. Laura Chico  (10/27/25)
Alto Neuroscience Inc. (ANRO:NYSE) completed a US$50 million equity raise and announced plans to accelerate development of its recently acquired asset in treatment-resistant depression, noted a Wedbush report. More >

US Biopharma In-Licenses 3 New Assets
Source: Dr. Martin Fan  (10/24/25)
Zenas BioPharma Inc.'s (ZBIO:NASDAQ) target price is increased 14% to reflect the Phase 3 investigative multiple sclerosis drug included in this recent deal, noted a Wedbush report. More >

Chen's High-Grade Gold, Silver Plays for Q4
Source: Streetwise Reports  (10/23/25)
It has been quite a year for precious metals such as gold and silver, and Chen Lin's top stock picks for the quarter bear that out. Which companies have the most upside? More >

AI Cancer Discovery Shows Breakthrough in Brain-Targeting Treatment
Source: Streetwise Reports  (10/20/25)
Rakovina Therapeutics Inc. (RKV:TSX.V) is set to unveil new preclinical data from its AI-driven ATR inhibitor program at a major international cancer conference in Boston. The findings highlight strong efficacy and blood-brain barrier permeability, a potential breakthrough for hard-to-treat tumors and brain metastases. More >

Cleantech Co. Advances Antimicrobial Wound Care Breakthrough
Source: Streetwise Reports  (10/17/25)
Cleantech innovation company BioLargo Inc. (BLGO:OTCQX) announced that subsidiary Clyra Medical Technologies is making significant strides. Read why one analyst says the technology is on "the cusp of commercialization." More >

Biopharma's New MASH Drug Has Two MOAs
Source: Patrick Trucchio  (10/15/25)
Altimmune Inc.'s (ALT:NASDAQ) pemvidutide achieves metabolic improvement and directs hepatic anti-fibrotic activity with singular dosing, noted an H.C. Wainwright & Co. report. More >

Life Sciences Co. Reports Strong Survival Data
Source: Jason Kolbert  (10/13/25)
OS Therapies Inc.'s (OSTX:NYSEAMERICAN) trial results are for its new immunotherapy in fully resected pulmonary metastatic osteosarcoma, noted a D. Boral Capital report. More >

Healthcare Tech Firm Finds Big U.S. Opportunity
Source: Streetwise Reports  (10/9/25)
Healthcare data firm OneMedNet Corporation (Nasdaq: ONMD) partners with Palantir Technologies Inc. (PLTR:NASDAQ) to analyze over 5 billion claims and 131 million exams, unlocking a possible massive U.S. breakthrough in AI-driven research. More >

Pharma Announces Faster Approval Pathway for Neurodegenerative Disease
Source: Dr. Leland Gershell and Rohan Mathur  (10/9/25)
Lexeo Therapeutics Inc. (LXEO:NASDAQ) announces a faster approval pathway for LX2006 in Friedreich's ataxia (FA). Find out why two analysts believe the company is emerging as a leader in developing transformative gene therapies for rare cardiac and neurodegenerative diseases. More >

Biotech Firm Uncovers Breakthrough Gene Therapy in New York
Source: Streetwise Reports  (10/9/25)
Lexeo Therapeutics Inc. (LXEO:NASDAQ) advanced its LX2006 program after new FDA feedback supported an accelerated approval path. Read how interim data showed strong cardiac and neurological improvements, prompting bullish analyst upgrades. More >

Therapeutics Company Advances Gene Therapy Breakthrough
Source: Mitchell Kapoor and Dr. Raghuram Selvaraju  (10/9/25)
In an updated research note on October 7, H.C. Wainwright & Co. analysts Mitchell Kapoor and Dr. Raghuram Selvaraju note significant risk reduction for Lexeo Therapeutics Inc. (LXEO:NASDAQ) as formal alignment with the FDA makes its new drug increasingly likely to gain approval. More >